Preventive attitude of physicians to avoid OHSS in IVF patients.
The ovarian hyperstimulation syndrome (OHSS) is a dramatic iatrogenic complication of fertility treatment. There is no consensus about its prevention strategies. We assessed whether physicians modify their preventive attitude in relation to clinical risk factors and to the oestradiol response chart. Three case scenarios with three levels of risk factors for OHSS were constructed. For each case scenario, four different charts of the oestradiol curve were described (peak serum oestradiol of 3590 or 6590 pg/ml obtained after a shorter or longer period). At random, we sent three out of the 12 artificially constructed case scenarios to 573 physicians who are members of the European Society of Human Reproduction and Embryology (ESHRE). They were asked whether they would cancel the cycle, take preventive measures or proceed to a regular IVF. A total of 389 cases from 130 different physicians was analysed. Globally, in 23% of the cases the physicians would proceed to a regular IVF. This decision varied significantly according to the risk level (between 38% in low risk to 8% in high risk cases; P < 0.01) and in relation to the oestradiol curve (P < 0.01). In 11% of the cases they would cancel the cycle and in 66% take some preventive measures. Among the selected preventive measures, coasting was by far the most popular choice (60%), followed by the use of i.v. albumin or hydroxyaethyl starch solution (36%) and cryo-preservation of all embryos (33%). In view of the sparse data as to whether coasting is really an effective method, and on how it should be carried out, we suggest that there is an urgent need to evaluate coasting as a preventive method in a large randomized trial in order to properly assess its efficiency and to provide precise guidelines for its use.
Delvigne
A
A
IVF Centre, Department of Obstetrics-Gynaecology, University Hospital St Pierre, Free University of Brussels ULB, Brussels, Belgium. annick.delvigne@yucom.be
Rozenberg
S
S
D001291:Attitude of Health Personnel; D006063:Chorionic Gonadotropin / Q000008:administration & dosage; D015925:Cryopreservation; D004622:Embryo, Mammalian; D004958:Estradiol / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000008:administration & dosage; D016471:Ovarian Hyperstimulation Syndrome / Q000517:prevention & control*; D010820:Physicians; D011446:Prospective Studies; D012307:Risk Factors
D006063:Chorionic Gonadotropin; D006895:Hydroxyethyl Starch Derivatives; D004958:Estradiol